Pacira

In: Finance

Dmitry Vinogradov Barclays downgraded Pacira BioSciences (NASDAQ:PCRX) to equal weight from overweight following the U.S. FDA’s recent approval of a generic version of the company’s best-selling drug, Exparel (bupivacaine liposome). The firm cut its target price to $25 from $38 (~15% upside based on Wednesday’s close). Barclays noted that 78%Continue Reading

In: Finance

jmiks Pacira BioSciences (NASDAQ:PCRX) plummeted ~25% in Tuesday trading after the U.S. FDA approved a generic version of Exparel (bupivacaine liposome), a non-opioid used for post-surgery local anasthesia. The agency approved an abbreviated New Drug Application for a generic version from Hengrui Pharma. Exparel is by far Pacira’s biggest revenueContinue Reading